B. Riley downgraded Intercept to Neutral from Buy with a price target of $19, up from $15, after Alfasigma agreed to acquire Intercept for $19 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICPT:
- Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
- Alfasigma to acquire Intercept for $19.00 per share in cash
- Intercept price target raised to $20 from $18 at Canaccord
- Intercept raises FY23 Ocaliva net sales view to $320M-$340M from $310M-$340M
- Intercept reports Q2 EPS (14c), consensus (51c)